There is no doubt that the growing incidence of ALF, FHF and ACLF, together with the shortage of organs for donation, will drive the development of this type of support therapies.
Sin duda, la creciente incidencia de FHA, FHF y FHCA, sumada a la pobre oferta de donación de órganos, impulsará este tipo de terapias de soporte.